Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.85
ARDM's Cash-to-Debt is ranked lower than
55% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.05 vs. ARDM: 0.85 )
Ranked among companies with meaningful Cash-to-Debt only.
ARDM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.29  Med: 5.24 Max: No Debt
Current: 0.85
Equity-to-Asset -0.46
ARDM's Equity-to-Asset is ranked lower than
99% of the 731 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. ARDM: -0.46 )
Ranked among companies with meaningful Equity-to-Asset only.
ARDM' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.83  Med: 0.52 Max: 0.93
Current: -0.46
-1.83
0.93
Debt-to-Equity -2.34
ARDM's Debt-to-Equity is ranked lower than
99.99% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.30 vs. ARDM: -2.34 )
Ranked among companies with meaningful Debt-to-Equity only.
ARDM' s Debt-to-Equity Range Over the Past 10 Years
Min: -85.03  Med: 0.13 Max: 55.12
Current: -2.34
-85.03
55.12
Piotroski F-Score: 2
Altman Z-Score: -48.49
Beneish M-Score: -1.48
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -158.38
ARDM's Operating Margin % is ranked lower than
95% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.95 vs. ARDM: -158.38 )
Ranked among companies with meaningful Operating Margin % only.
ARDM' s Operating Margin % Range Over the Past 10 Years
Min: -15395.9  Med: -470.36 Max: -11.49
Current: -158.38
-15395.9
-11.49
Net Margin % -196.65
ARDM's Net Margin % is ranked lower than
95% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.06 vs. ARDM: -196.65 )
Ranked among companies with meaningful Net Margin % only.
ARDM' s Net Margin % Range Over the Past 10 Years
Min: -16891.28  Med: -549.46 Max: 13.86
Current: -196.65
-16891.28
13.86
ROE % -841.00
ARDM's ROE % is ranked lower than
98% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.91 vs. ARDM: -841.00 )
Ranked among companies with meaningful ROE % only.
ARDM' s ROE % Range Over the Past 10 Years
Min: -841  Med: -183.67 Max: 12.78
Current: -841
-841
12.78
ROA % -74.18
ARDM's ROA % is ranked lower than
96% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. ARDM: -74.18 )
Ranked among companies with meaningful ROA % only.
ARDM' s ROA % Range Over the Past 10 Years
Min: -108.56  Med: -68.01 Max: 8.91
Current: -74.18
-108.56
8.91
ROC (Joel Greenblatt) % -5938.74
ARDM's ROC (Joel Greenblatt) % is ranked lower than
96% of the 793 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.48 vs. ARDM: -5938.74 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ARDM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -11062.32  Med: -683.16 Max: 1095.34
Current: -5938.74
-11062.32
1095.34
3-Year Revenue Growth Rate -77.00
ARDM's 3-Year Revenue Growth Rate is ranked lower than
98% of the 634 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. ARDM: -77.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ARDM' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -81.4  Med: -12.5 Max: 136.2
Current: -77
-81.4
136.2
3-Year EBITDA Growth Rate -1.20
ARDM's 3-Year EBITDA Growth Rate is ranked lower than
69% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. ARDM: -1.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ARDM' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -61.1  Med: -26.4 Max: 10.6
Current: -1.2
-61.1
10.6
3-Year EPS without NRI Growth Rate -1.90
ARDM's 3-Year EPS without NRI Growth Rate is ranked lower than
63% of the 576 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.60 vs. ARDM: -1.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ARDM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -56.3  Med: -30.4 Max: 20
Current: -1.9
-56.3
20
GuruFocus has detected 2 Warning Signs with Aradigm Corp $ARDM.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ARDM's 30-Y Financials

Financials (Next Earnings Date: 2017-11-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

ARDM Guru Trades in Q3 2016

John Paulson 146,918 sh (+122.93%)
Steven Cohen 320,585 sh (unchged)
First Eagle Investment 3,854,730 sh (unchged)
» More
Q4 2016

ARDM Guru Trades in Q4 2016

Jim Simons 27,900 sh (New)
John Paulson 192,727 sh (+31.18%)
First Eagle Investment 3,854,730 sh (unchged)
Steven Cohen Sold Out
» More
Q1 2017

ARDM Guru Trades in Q1 2017

John Paulson 192,727 sh (unchged)
First Eagle Investment 3,854,730 sh (unchged)
Jim Simons Sold Out
» More
Q2 2017

ARDM Guru Trades in Q2 2017

Jim Simons 11,202 sh (New)
John Paulson 192,727 sh (unchged)
First Eagle Investment 3,854,730 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ARDM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2016-12-31 Add 31.18%$1.59 - $6.82 $ 1.96-55%192,727
John Paulson 2016-09-30 Add 122.93%0.01%$4.13 - $6.88 $ 1.96-60%146,918
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 334510    SIC: 3845
Compare:XCNQ:IAN, NAS:BPTH, NAS:IMMY, OTCPK:STNY, NAS:OREX, NAS:PTX, OTCPK:MCOA, OTCPK:SENZ, OTCPK:CVSI, NAS:PSDV, NAS:JNP, NAS:FCSC, NAS:SNOA, NAS:EVOK, NAS:ATXI, OTCPK:CXBS, NAS:APRI, OTCPK:KAYS, NAS:SCYX, OTCPK:AOLS » details
Headquarter Location:USA
Aradigm Corp is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases.

Aradigm Corp.

Ratios

vs
industry
vs
history
PS Ratio 3.94
ARDM's PS Ratio is ranked lower than
81% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. ARDM: 3.94 )
Ranked among companies with meaningful PS Ratio only.
ARDM' s PS Ratio Range Over the Past 10 Years
Min: 1.21  Med: 12.31 Max: 1146.67
Current: 3.94
1.21
1146.67
EV-to-EBIT -2.68
ARDM's EV-to-EBIT is ranked lower than
99.99% of the 559 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.11 vs. ARDM: -2.68 )
Ranked among companies with meaningful EV-to-EBIT only.
ARDM' s EV-to-EBIT Range Over the Past 10 Years
Min: -17.8  Med: -1.8 Max: 19.3
Current: -2.68
-17.8
19.3
EV-to-EBITDA -2.70
ARDM's EV-to-EBITDA is ranked lower than
99.99% of the 587 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.50 vs. ARDM: -2.70 )
Ranked among companies with meaningful EV-to-EBITDA only.
ARDM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -18.5  Med: -1.8 Max: 18.3
Current: -2.7
-18.5
18.3
EV-to-Revenue 4.22
ARDM's EV-to-Revenue is ranked lower than
76% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.22 vs. ARDM: 4.22 )
Ranked among companies with meaningful EV-to-Revenue only.
ARDM' s EV-to-Revenue Range Over the Past 10 Years
Min: -17  Med: 7.8 Max: 819.1
Current: 4.22
-17
819.1
Current Ratio 2.52
ARDM's Current Ratio is ranked lower than
73% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. ARDM: 2.52 )
Ranked among companies with meaningful Current Ratio only.
ARDM' s Current Ratio Range Over the Past 10 Years
Min: 0.94  Med: 4.2 Max: 21.99
Current: 2.52
0.94
21.99
Quick Ratio 2.52
ARDM's Quick Ratio is ranked lower than
59% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.82 vs. ARDM: 2.52 )
Ranked among companies with meaningful Quick Ratio only.
ARDM' s Quick Ratio Range Over the Past 10 Years
Min: 0.94  Med: 4.18 Max: 21.99
Current: 2.52
0.94
21.99
Days Sales Outstanding 13.00
ARDM's Days Sales Outstanding is ranked higher than
62% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.70 vs. ARDM: 13.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARDM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.34  Med: 14.93 Max: 571.49
Current: 13
2.34
571.49

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.60
ARDM's 3-Year Average Share Buyback Ratio is ranked higher than
73% of the 473 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.10 vs. ARDM: -0.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ARDM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -63.3  Med: -35.3 Max: -0.6
Current: -0.6
-63.3
-0.6

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.33
ARDM's Price-to-Median-PS-Value is ranked higher than
75% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. ARDM: 0.33 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ARDM' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.1  Med: 0.52 Max: 98.29
Current: 0.33
0.1
98.29
Earnings Yield (Greenblatt) % -37.31
ARDM's Earnings Yield (Greenblatt) % is ranked lower than
99% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. ARDM: -37.31 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ARDM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -7941.7  Med: -47.75 Max: 73513.7
Current: -37.31
-7941.7
73513.7

More Statistics

Revenue (TTM) (Mil) $9.54
EPS (TTM) $ -1.27
Beta1.25
Short Percentage of Float4.37%
52-Week Range $0.78 - 7.19
Shares Outstanding (Mil)15.11
» More Articles for ARDM

Headlines

Articles On GuruFocus.com
First Eagle Adds to Stake in Aradigm Apr 28 2016 
Supernus Pharmaceuticals Reports Insider Buys Mar 26 2013 
Eveillard’s First Eagle Seizes 45% of Pharamaceutical Company, Aradigm Dec 19 2012 

More From Other Websites
Aradigm Announces FDA Acceptance of NDA for Linhaliq with Priority Review Status Sep 25 2017
Aradigm to Present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26 Sep 22 2017
Aradigm to Host KOL Call on Infection Management in Non-Cystic Fibrosis Bronchiectasis Patients Sep 15 2017
Aradigm Announces Upcoming Data Presentations in Non-Cystic Fibrosis Bronchiectasis at the European... Sep 05 2017
Aradigm Awarded NIH Grant to Investigate the Treatment of Pulmonary Non-Tuberculous Mycobacterial... Aug 15 2017
Aradigm posts 2Q profit Aug 10 2017
Aradigm Announces Second Quarter 2017 Financial Results Aug 10 2017
Aradigm Submits New Drug Application (NDA) to FDA for U.S. Marketing Approval of Linhaliq in... Jul 27 2017
Aradigm reports 1Q loss May 15 2017
Aradigm Announces First Quarter 2017 Financial Results May 15 2017
Aradigm Announces Fourth Quarter 2016 and Full Year Financial Results Mar 28 2017
Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2017... Feb 09 2017
Aradigm to Present at 9th Annual Biotech Showcase Conference on January 9 Jan 06 2017
Aradigm Lung Infection Antibiotic Fails Trial (ARDM) Dec 02 2016
Don’t Write Off Aradigm Corporation (ARDM) Just Yet Dec 02 2016
Aradigm Shares Plunge After Releasing Mixed Clinical Trial Results For Pulmaquin Dec 01 2016
Aradigm posts mixed late-stage data on inhaled antibiotic Dec 01 2016
Aradigm Announces Top-Line Results from Two Phase 3 Studies Evaluating Pulmaquin for the Chronic... Dec 01 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}